PharmD Info

A forum for Indian Pharmacy Professionals

Medication Therapy Management. Clinical Pharmacy Services, Pharmacotherapy Case Discussions, Hospital Activity Documentation, Online Pharmacy,
Forum rules: Dear User, Kindly read our forum rules before you proceed with our PharmD Info, Your first 5 posts/topics requires moderator approval and this website is purely meant for educational and knowledge sharing purpose only so you should not make any topics/replies/messages which criticize, threaten or abuse any member, pharmacy governing bodies and organizations. Your post will be deleted automatically by our BB Pruning System if your topic is not viewed by members for more than 5 days. So, make sure that your topics and its related contents are unique and valuable. We expect you to be an active member of our forum to continue with your free membership.Kindly note that if a member received more than five warnings from moderator/members they will be blocked automatically by our Bulletin Board system.
  • User avatar
#3297
Aspirin is recommended as a lifelong therapy that should never be interrupted for patients with cardiovascular disease.

Clopidogrel therapy is mandatory for six weeks after the placement of bare-metal stents, three to six months after myocardial infarction, and at least 12 months after placement of drug-eluting stents.

Because of the hypercoagulable state induced by surgery, early withdrawal of antiplatelet therapy for secondary prevention of cardiovascular disease increases the risk of postoperative myocardial infarction and death five- to 10-fold in stented patients who are on continuous dual antiplatelet therapy.

The shorter the time between revascularization and surgery, the higher the risk of adverse cardiac events. Elective surgery should be postponed beyond these periods, whereas vital, semi-urgent, or urgent operations should be performed under continued dual antiplatelet therapy.

The risk of surgical haemorrhage is increased by approximately 20 percent by aspirin or clopidogrel alone, and 50 percent by dual antiplatelet therapy.

The present clinical data suggest that the risk of a cardiovascular event when stopping antiplatelet agents preoperatively is higher than the risk of surgical bleeding when continuing these drugs, except during surgery in a closed space (e.g., intracranial, posterior eye chamber) or surgeries associated with massive bleeding and difficult hemostasis.

References: https://www.aafp.org/afp/2010/1215/p1484.html
Attachments:
(632.96 KiB) Downloaded 77 times
(142.76 KiB) Downloaded 79 times
(208.04 KiB) Downloaded 62 times
(212.5 KiB) Downloaded 92 times
Similar Topics
Topics Statistics Last post
0 Replies 
5472 Views
by rahmatulla.syed
25 Oct 2017, 17:43
2 Replies 
2574 Views
by Prajith
18 Jan 2017, 10:58
3 Replies 
1978 Views
by Naghul adhithya k s
03 Mar 2020, 00:26
1 Replies 
688 Views
by Mugilraj
01 Mar 2020, 11:39
Low Level Laser Therapy (LLLT)
by Dr.SandeepMahapatra  - 22 Aug 2019, 15:34  - In: Doctors Forum
0 Replies 
842 Views
by Dr.SandeepMahapatra
22 Aug 2019, 15:34

How to search FDA 21 CRF database effectively in […]

All the Questions and Answers on SUPAC IR Compone[…]

Latest FDA Scale Up and Post Approval Changes Guid[…]

Dear colleague, Greetings from Believers Church M[…]

Join Us Today